Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel
NASDAQ:IMRX

Immuneering Q1 2026 Earnings Report

Immuneering logo
$5.22 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$5.20 -0.02 (-0.44%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Immuneering EPS Results

Actual EPS
N/A
Consensus EPS
-$0.30
Beat/Miss
N/A
One Year Ago EPS
N/A

Immuneering Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immuneering Announcement Details

Quarter
Q1 2026
Date
5/11/2026
Time
Before Market Opens
Conference Call Date
Monday, May 11, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Immuneering Earnings Headlines

We're Hopeful That Immuneering (NASDAQ:IMRX) Will Use Its Cash Wisely
May 6 at 7:40 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/were-hopeful-immuneering-nasdaq-imrx-145323224.html
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and McKesson (MCK)
April 23, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/MCK/pressreleases/1445806/analysts-offer-insights-on-healthcare-companies-immuneering-imrx-and-mckesson-mck/
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.tc pixel
May 8 at 1:00 AM  |  Weiss Ratings (Ad)
Analysts Offer Insights on Healthcare Companies: Passage Bio (PASG) and Immuneering (IMRX)
April 21, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1427322/analysts-offer-insights-on-healthcare-companies-passage-bio-pasg-and-immuneering-imrx/
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
April 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/21/3278411/0/en/immuneering-to-present-new-survival-data-from-first-line-pancreatic-cancer-patients-treated-with-atebimetinib-mgnp-in-an-oral-presentation-at-the-2026-asco-annual-meeting.html
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic ...
April 21, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/immuneering-presents-genetic-data-at-aacr-annual-meeting-demonstrating-mechanism-to-improve-durability-and-survival-supporting-use-of-atebimetinib-in-first-line-pancreatic-cancer-and-beyond-1036037799
See More Immuneering Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immuneering? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immuneering and other key companies, straight to your email.

About Immuneering

Immuneering (NASDAQ:IMRX) (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy. Immuneering also maintains discovery- and preclinical-stage programs targeting inflammatory and immuno-oncology indications. Through strategic collaborations and licensing partnerships, the company extends the application of its computational platform across multiple therapeutic areas and works alongside pharmaceutical partners to co-develop novel treatments.

Founded in 2016, Immuneering is headquartered in Cambridge, Massachusetts, and operates research facilities in the United States. After completing its initial public offering on the Nasdaq in early 2021, the company has continued to expand its computational infrastructure, diversify its pipeline through in-house research and external collaborations, and advance its mission to bring more effective, AI-driven therapies to patients worldwide.

View Immuneering Profile
Earnings Tools